Drug intelligence / Profile preview

CP106

Development stage: Preclinical
Lead developer: Contera Pharma
Modality: Small Molecules
Administration: Parenteral

Overview

CP106 is a long-acting injectable (LAI) formulation of the atypical antipsychotic risperidone, currently in preclinical development by Consegna Pharma for the treatment of schizophrenia. Utilizing a proprietary delivery technology, CP106 is designed to provide a 60-day sustained release of the medication, potentially improving patient adherence compared to shorter-acting formulations. Risperidone acts primarily as an antagonist at dopamine D2 and serotonin 5-HT2A receptors, helping to manage the positive and negative symptoms of psychiatric disorders.

Other names: risperidone

Targets

HTR2A (Serotonin receptor 5-HT2A)DRD2 (Dopamine D2 Receptor)

Beyond the preview

Go deeper on CP106.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CP106.

Explore the full profile